Critical role of post-transcriptional regulation for IFN-γ in tumor-infiltrating T cells

References

• Besser MJ, Jessen WJ, Miller SJ, Kluwe L, Mautner VF, Wallace MR, Lázaro C, Page GP, Worley PF, Aronow BJ, et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2010;16:2646–2655. doi:10.1158/1078-0432.CCR-10-0613.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Jessen WJ, Miller SJ, Kluwe L, Mautner VF, Wallace MR, Lázaro C, Page GP, Worley PF, Aronow BJ, et al. CD8+ enriched ‘young’ tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res. 2010;16:6122–6131. doi:10.1158/1078-0432.CCR-10-0613.
   PubMed Web of Science ®Google Scholar
• Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107–1111. doi:10.1038/35074122.
   PubMed Web of Science ®Google Scholar
• Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity. 1994;1:447–456. doi:10.1016/1074-7613(94)90087-6.
   PubMed Web of Science ®Google Scholar
• Nirschl CJ, Suárez-Fariñas M, Izar B, Prakadan S, Dannenfelser R, Tirosh I, Liu Y, Zhu Q, Devi KSP, Carroll SL, et al. IFNgamma-dependent tissue-immune homeostasis is co-opted in the tumor microenvironment. Cell. 2017;170:127–141.e15. doi:10.1016/j.cell.2017.06.016.
   PubMed Web of Science ®Google Scholar
• Patel, S. J., et al. Identification of essential genes for cancer immunotherapy. Nature. 2017;548:537–542. doi:10.1038/nature23004.
   PubMed Web of Science ®Google Scholar
• Slattery ML, Lundgreen A, Bondurant KL, Wolff RK. Interferon-signaling pathway: associations with colon and rectal cancer risk and subsequent survival. Carcinogenesis. 2011;32:1660–1667. doi:10.1093/carcin/bgr189.
   PubMed Web of Science ®Google Scholar
• Appay V, Jandus C, Voelter V, Reynard S, Coupland SE, Rimoldi D, Lienard D, Guillaume P, Krieg AM, Cerottini J-C, et al. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol. 2006;177:1670–1678. doi:10.4049/jimmunol.177.3.1670.
   PubMed Web of Science ®Google Scholar
• Baitsch L, Seo D, Belfort-DeAguiar R, Lacadie C, Dzuira J, Naik S, Amarnath S, Constable RT, Sherwin RS, Sinha R. Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. J Clin Invest. 2011;121:2350–2360. doi:10.1172/JCI57873.
   PubMed Web of Science ®Google Scholar
• Harlin H, Kuna TV, Peterson AC, Meng Y, Gajewski TF. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother. 2006;55:1185–1197. doi:10.1007/s00262-005-0118-2.
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S. 2002;99:12293–12297. doi:10.1073/pnas.192461099.
   PubMed Web of Science ®Google Scholar
• Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734–1736. doi:10.1126/science.271.5256.1734.
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15:486–499. doi:10.1038/nri3862.
   PubMed Web of Science ®Google Scholar
• Chang C-H, Qiu J, O’Sullivan D, Buck M, Noguchi T, Curtis J, Chen Q, Gindin M, Gubin M, van der Windt GW, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162:1229–1241. doi:10.1016/j.cell.2015.08.016.
   PubMed Web of Science ®Google Scholar
• Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, Bell LN, Karoly ED, Freeman GJ, Petkova V, Seth P, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun. 2015;6:6692. doi:10.1038/ncomms7692.
   PubMed Web of Science ®Google Scholar
• Ho P-C, Bihuniak J, Macintyre A, Staron M, Liu X, Amezquita R, Tsui Y-C, Cui G, Micevic G, Perales J, et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell. 2015;162:1217–1228. doi:10.1016/j.cell.2015.08.012.
   PubMed Web of Science ®Google Scholar
• Anderson P. Post-transcriptional regulons coordinate the initiation and resolution of inflammation. Nat Rev Immunol. 2010;10:24–35. doi:10.1038/nri2685.
   PubMed Web of Science ®Google Scholar
• Kafasla P, Skliris A, Kontoyiannis DL. Post-transcriptional coordination of immunological responses by RNA-binding proteins. Nat Immunol. 2014;15:492–502. doi:10.1038/ni.2884.
   PubMed Web of Science ®Google Scholar
• Salerno F, Wolkers MC. T-cells require post-transcriptional regulation for accurate immune responses. Biochem Soc Trans. 2015;43:1201–1207. doi:10.1042/BST20150154.
   PubMed Web of Science ®Google Scholar
• Turner M, Galloway A, Vigorito E. Noncoding RNA and its associated proteins as regulatory elements of the immune system. Nat Immunol. 2014;15:484–491. doi:10.1038/ni.2887.
   PubMed Web of Science ®Google Scholar
• Salerno F, Paolini NA, Stark R, von Lindern M, Wolkers MC. Distinct PKC-mediated posttranscriptional events set cytokine production kinetics in CD8 + T cells. Proc Natl Acad Sci. 2017;114:9677–9682. doi:10.1073/pnas.1704227114.
   PubMed Web of Science ®Google Scholar
• Salerno F, Guislain A, Cansever D, Wolkers MC. TLR-mediated innate production of IFN-γ by CD8 + T cells is independent of glycolysis. J Immunol. 2016;196:3695–3705. doi:10.4049/jimmunol.1501997.
   PubMed Web of Science ®Google Scholar
• Hodge DL, Berthet C, Coppola V, Kastenmüller W, Buschman MD, Schaughency PM, Shirota H, Scarzello AJ, Subleski JJ, Anver MR, et al. IFN-gamma AU-rich element removal promotes chronic IFN-gamma expression and autoimmunity in mice. J Autoimmun. 2014;53:33–45. doi:10.1016/j.jaut.2014.02.003.
   PubMed Web of Science ®Google Scholar
• Zehn D, Lee S, Bevan M. Complete but curtailed T cell response to very low affinity antigen. Nature. 2009;458:211–214. doi:10.1038/nature07657.
   PubMed Web of Science ®Google Scholar
• Masopust D, Vezys V, Marzo AL, Lefrancois L. Preferential localization of effector memory cells in nonlymphoid tissue. Science. 2001;291:2413–2417. doi:10.1126/science.1058867.
   PubMed Web of Science ®Google Scholar
• Soudja SM, Ruiz AL, Marie JC, Lauvau G. Inflammatory monocytes activate memory CD8(+) T and innate NK lymphocytes independent of cognate antigen during microbial pathogen invasion. Immunity. 2012;37:549–562. doi:10.1016/j.immuni.2012.05.029.
   PubMed Web of Science ®Google Scholar
• De Witte MA, Bledi Y, Atallah M, Trahtemberg U, Verbovetski I, Nahari E, Zelig O, Linial M, Mevorach D. Targeting self-antigens through allogeneic TCR gene transfer. Blood. 2006;108. doi:10.1182/blood-2006-03-013334.
   Web of Science ®Google Scholar
• Denton AE, Russ BE, Doherty PC, Rao S, Turner SJ. Differentiation-dependent functional and epigenetic landscapes for cytokine genes in virus-specific CD8+ T cells. Proc Natl Acad Sci U S A. 2011;108:15306–15311. doi:10.1073/pnas.1112520108.
   PubMed Web of Science ®Google Scholar
• Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol. 1997;15:749–795. doi:10.1146/annurev.immunol.15.1.749.
   PubMed Web of Science ®Google Scholar
• Parker BS, Rautela J, Hertzog PJ. Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer. 2016;16:131–144. doi:10.1038/nrc.2016.14.
   PubMed Web of Science ®Google Scholar
• Goncalves R, Zhang X, Cohen H, Debrabant A, Mosser DM, Cammas F, Alt FW, Losson R, Reina-San-Martin B. Platelet activation attracts a subpopulation of effector monocytes to sites of Leishmania major infection. J Exp Med. 2011;208:1253–1265. doi:10.1084/jem.20110118.
   PubMed Web of Science ®Google Scholar
• Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med. 1992;176:287–292. doi:10.1084/jem.176.1.287.
   PubMed Web of Science ®Google Scholar
• Zippelius, A., et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions : A state of local functional tolerance effector function of human tumor-specific CD8 T cells in melanoma lesions : A State of local functional tolerance. Cancer Res. 2004;64:2865–2873. doi:10.1158/0008-5472.CAN-03-3066.
   PubMed Web of Science ®Google Scholar
• Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol. 2005;17:133–144. doi:10.1093/intimm/dxh194.
   PubMed Web of Science ®Google Scholar
• Topalian, S. L., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454. doi:10.1056/NEJMoa1114705.
   PubMed Web of Science ®Google Scholar
• Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, Sasmal DK, Huang J, Kim JM, Mellman I, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017;355:1428–1433. doi:10.1126/science.aaf1292.
   PubMed Web of Science ®Google Scholar
• Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, Konieczny BT, Daugherty CZ, Koenig L, Yu K, et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science. 2017;355:1423–1427. doi:10.1126/science.aaf0683.
   PubMed Web of Science ®Google Scholar
• Pauken KE, Page SE, Evans CD, Osaki M. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science. 2016;354:1160–1165. doi:10.1126/science.aal1794.
   PubMed Web of Science ®Google Scholar
• Schietinger A, Philip M, Krisnawan VE, Chiu EY, Delrow JJ, Basom RS, Lauer P, Brockstedt DG, Knoblaugh SE, Hämmerling GJ, et al. Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis. Immunity. 2016;45:389–401. doi:10.1016/j.immuni.2016.07.011.
   PubMed Web of Science ®Google Scholar
• Philip M, Fairchild L, Sun L, Horste EL, Camara S, Shakiba M, Scott AC, Viale A, Lauer P, Merghoub T, et al. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature. 2017;545:452–456. doi:10.1038/nature22367.
   PubMed Web of Science ®Google Scholar
• Doller A, Pfeilschifter J, Eberhardt W. Signalling pathways regulating nucleo-cytoplasmic shuttling of the mRNA-binding protein HuR. Cell Signal. 2008;20:2165–2173. doi:10.1016/j.cellsig.2008.05.007.
   PubMed Web of Science ®Google Scholar
• Zhu P, Jiang W, Cao L, Yu W, Pei Y, Yang X, Wan B, Liu JO, Yi Q, Yu L. IL-2 mRNA stabilization upon PMA stimulation is dependent on NF90-Ser647 phosphorylation by protein kinase CbetaI. J Immunol. 2010;185:5140–5149. doi:10.4049/jimmunol.1000849.
   PubMed Web of Science ®Google Scholar
• Lindstein T, June CH, Ledbetter JA, Stella G, Thompson CB. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science. 1989;244:339–343. doi:10.1126/science.244.4910.1244-b.
   PubMed Web of Science ®Google Scholar
• Dobbins J, Gagnon E, Godec J, Pyrdol J, Vignali DAA, Sharpe AH, Wucherpfennig KW. Binding of the cytoplasmic domain of CD28 to the plasma membrane inhibits Lck recruitment and signaling. Sci Signal. 2016;9:ra75. doi:10.1126/scisignal.aaf0626.
   PubMed Web of Science ®Google Scholar
• Yokosuka TN, Saito T. Dynamic regulation of T-cell costimulation through TCR-CD28 microclusters. Immunol Rev. 2009;229:27–40. doi:10.1111/j.1600-065X.2009.00779.x.
   PubMed Web of Science ®Google Scholar
• Pei Y, Zhu P, Dang Y, Wu J, Yang X, Wan B, Liu JO, Yi Q, Yu L. Nuclear export of NF90 to stabilize IL-2 mRNA is mediated by AKT-dependent phosphorylation at Ser647 in response to CD28 costimulation. J Immunol. 2008;180:222–229. doi:10.4049/jimmunol.180.1.222.
   PubMed Web of Science ®Google Scholar
• Sheppard K-A, Fitz LJ, Lee JM, Benander C, George JA, Wooters J, Qiu Y, Jussif JM, Carter LL, Wood CR, et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 2004;574:37–41. doi:10.1016/j.febslet.2004.07.083.
   PubMed Web of Science ®Google Scholar
• Salerno F, Engels S, van Den Biggelaar M, van Alphen FPJ, Guislain A, Zhao W, Hodge DL, Bell SE, Medema JP, von Lindern M, et al. Translational repression of pre-formed cytokine-encoding mRNA prevents chronic activation of memory T cells. Nat Immunol. 2018;19:828–837. doi:10.1038/s41590-018-0155-6.
   PubMed Web of Science ®Google Scholar
• Benci JL, Liang Y-L, Nowell CJ, Halls ML, Wookey PJ, Dal Maso E, Inoue A, Christopoulos A, Wootten D, Sexton PM. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell. 2016;167:1540–1554.e12. doi:10.1016/j.cell.2016.09.021.
   PubMed Web of Science ®Google Scholar
• Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+T cells directly within the tumor microenvironment. J Immunother Cancer. 2014;2:1–14. doi:10.1186/2051-1426-2-3.
   PubMedGoogle Scholar